Neuronetrix has been selected to present at the 6th Annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD) in San Diego, CA, on Nov 15, 2013. CTAD is the foremost conference where leading pharmaceutical companies discuss their strategic plans for drug development efforts to treat Alzheimer’s disease.
Neuronetrix will present novel methods for analyzing complex electrophysiological measures of cognitive function. The data was collected as part of a large, multi-center clinical trial with over 200 subjects using the company’s COGNISION™ System. “Pharmaceutical companies demand sensitive, reliable, reproducible measures of the cognitive effects of treatment… COGNISION™ provides these measures,” said KC Fadem, CEO of Neuronetrix. “This conference will give Neuronetrix the opportunity to showcase our game-changing technology.”